Research ExplorerJournalsANTI-CANCER DRUG

ANTI-CANCER DRUG

Bibliographical data

ISSNs0959-4973
Electronic ISSN 1473-5741

Publications

A randomized phase II study to determine the efficacy and tolerability of two doses of eribulin plus lapatinib in trastuzumab-pretreated patients with HER-2-positive metastatic breast cancer (E-VITA)
Bischoff, J., Barinoff, J., Mundhenke, C., Bauerschlag, D. O., Costa, S-D., Herr, D., Lübbe, K., Marmé, F., Maass, N., von Minckwitz, G., Grischke, E-M., Müller, V., Schmidt, M., Gerber, B., Kümmel, S., Schumacher, C., Krabisch, P., Seiler, S., Thill, M., Nekljudova, V. & Loibl, S., 04.2019, In: ANTI-CANCER DRUG. 30, 4, p. 394-401 8 p.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Activity of nintedanib in germ cell tumors
Steinemann, G., Jacobsen, C., Gerwing, M., Hauschild, J., Amsberg, G., Höpfner, M., Nitzsche, B. & Honecker, F., 27.02.2016, In: ANTI-CANCER DRUG. 27, 2, p. 89-98

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Targeting DNA double-strand break repair: is it the right way for sensitizing cells to 5-fluorouracil?
El-Awady, R. A., Saleh, E. M. & Dahm-Daphi, J., 2010, In: ANTI-CANCER DRUG. 21, 3, p. 277-287 3.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Acquired vorinostat resistance shows partial cross-resistance to 'second-generation' HDAC inhibitors and correlates with loss of histone acetylation and apoptosis but not with altered HDAC and HAT activities.
Dedes, K. J., Dedes, I., Imesch, P., von Bueren, A., André, O., Fink, D. & Fedier, A., 2009, In: ANTI-CANCER DRUG. 20, 5, p. 321-333 5.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

The similarities of aromatase inhibitors outweigh the differences.
Jänicke, F., 2008, In: ANTI-CANCER DRUG. 19, 2, p. 7-9 2.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

An open-label, multicenter phase II trial of capecitabine in patients with cisplatin-refractory or relapsed germ cell tumors.
Oechsle, K., Honecker, F., Kollmannsberger, C., Rick, O., Grünwald, V., Mayer, F., Hartmann, J. T. & Bokemeyer, C., 2007, In: ANTI-CANCER DRUG. 18, 3, p. 273-276 3.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Weekly epirubicin and paclitaxel with granulocyte colony-stimulating factor support in previously untreated metastatic breast cancer patients: a phase II study.
Nisticò, C., Bria, E., Cuppone, F., Fornier, M., Sperduti, I., Carpino, A., Pace, A., Cognetti, F. & Terzoli, E., 2007, In: ANTI-CANCER DRUG. 18, 6, p. 687-692 6.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Anti-proliferative effect of peroxisome proliferator-activated receptor gamma agonists on human malignant melanoma cells in vitro.
Freudlsperger, C., Moll, I., Schumacher, U. & Dahl, A., 2006, In: ANTI-CANCER DRUG. 17, 3, p. 325-332 3.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Prospective multicenter phase II study of irinotecan as third-line therapy in metastatic colorectal cancer and progression after bolus and infusional 5-fluorouracil
Hartmann, J. T., Oechsle, K., Jäger, E., Reis, H. E., Haag, C., Niederle, N., Wilke, H-J., Pflüger, K-H., Batran, S. A., Büchele, T., Hofheinz, R. D., Kanz, L. & Bokemeyer, C., 06.2004, In: ANTI-CANCER DRUG. 15, 5, p. 473-7 5 p.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Gemcitabine and mitomycin C in advanced pancreatic cancer: a single-institution experience.
Tuinmann, G., Hegewisch-Becker, S., Zschaber, R., Kehr, A., Schulz, J. & Hossfeld, D. K., 2004, In: ANTI-CANCER DRUG. 15, 6, p. 575-579 6.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

View all (10)